Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-Sudan Vaccine in Healthy Adults
NCT06803342Phase 2Active, not recruiting
- Sponsor
- Sabin Vaccine Institute
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sudan virus disease (SVD) comparing cAd3-Sudan Vaccine with Placebo (2 arms). Primary endpoint: Percentage of vaccinated participants who develop Serious Adverse Events, Adverse Events, and Adverse Events of Special Interest at 1 year. Started Jun 2025; status: active, not recruiting.
02
Drugs
cAd3-EBO S
03
Conditions
Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT06803342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803342.